Richard Gedrich

3.4k total citations · 3 hit papers
42 papers, 2.5k citations indexed

About

Richard Gedrich is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Richard Gedrich has authored 42 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 20 papers in Pulmonary and Respiratory Medicine and 17 papers in Oncology. Recurrent topics in Richard Gedrich's work include Protein Degradation and Inhibitors (11 papers), Advanced Breast Cancer Therapies (7 papers) and Mast cells and histamine (7 papers). Richard Gedrich is often cited by papers focused on Protein Degradation and Inhibitors (11 papers), Advanced Breast Cancer Therapies (7 papers) and Mast cells and histamine (7 papers). Richard Gedrich collaborates with scholars based in United States, Germany and Switzerland. Richard Gedrich's co-authors include Craig B. Thompson, Robert H. Arch, Colin S. Duckett, Victor E. Nava, J. Marie Hardwick, Rollie J. Clem, D A Engel, Qianqian Zhou, Haolan Lu and Erika Hamilton and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Richard Gedrich

42 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors.

1996 533 citations Colin S. Duckett, Richard Gedrich et al. profile →
Tumor necrosis factor receptor-associated factors (TRAFs)—a family of adapter proteins that regulates life and death

1998 512 citations Robert H. Arch, Richard Gedrich et al. Genes & Development profile →
Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

2022 125 citations Xīn Gào, Howard A. Burris et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Richard Gedrich

Since Specialization

Citations

This map shows the geographic impact of Richard Gedrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Gedrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Gedrich more than expected).

Fields of papers citing papers by Richard Gedrich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Gedrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Gedrich. The network helps show where Richard Gedrich may publish in the future.

Co-authorship network of co-authors of Richard Gedrich

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Gedrich. A scholar is included among the top collaborators of Richard Gedrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Gedrich. Richard Gedrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader 2024 ·Molecular Cancer Therapeutics ·Lawrence B. Snyder, Taavi K. Neklesa, Ryan R. Willard, (unknown), Jennifer Pizzano, Nicholas Vitale, (unknown), M. Dorso, Walid Moghrabi, (unknown), Richard Gedrich, (unknown), I Taylor, John Houston	24
2	390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial 2023 ·Annals of Oncology ·Erika Hamilton, Hyo S. Han, Anne F. Schott, Antoinette R. Tan, Rita Nanda, Dejan Juric, (unknown), Pamela N. Münster, Bruno Fang, (unknown), (unknown), Richard Gedrich, Eric Zhi, (unknown), Weiwei Tan, (unknown), Jessica M. Perkins, Sibyl Anderson, Sara A. Hurvitz	12
3	256TiP TACTIVE-E: Phase Ib study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with everolimus in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer 2023 ·ESMO Open ·Alexander Philipovskiy, Anne F. Schott, Javier Cortés, Susan E. Ivie, Richard Gedrich, Eric Zhi, (unknown), Jessica M. Perkins, Erika Hamilton	2
4	1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations 2023 ·Annals of Oncology ·Daniel P. Petrylak, Benjamin Garmezy, John Shen, Arash Rezazadeh Kalebasty, Oliver Sartor, Robert Dreicer, Neeraj Agarwal, Maha Hussain, Ivor Percent, Elisabeth I. Heath, Richard Gedrich, Thomas Yu, Diane Healey, (unknown), Cora N. Sternberg, Xīn Gào	4
5	Abstract 432: Mechanisms of acquired resistance to ARV-471, a novel PROTAC® estrogen receptor degrader 2023 ·Cancer Research ·(unknown), (unknown), Wendy Wu, (unknown), (unknown), (unknown), Monica Andreoli, Elizabeth Bortolon, Jennifer Pizzano, Richard Gedrich, I Taylor	3
6	Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study 2022 ·Allergy ·Diego Alvarado, Marcus Maurer, Richard Gedrich, Scott B. Seibel, Michael Murphy, (unknown), J. Goldstein, Andrea Crocker, Laura Vitale, (unknown), Lawrence J. Thomas, Thomas Hawthorne, Tibor Keler, Diane Young, Elizabeth Crowley, Martin Kankam, Margo Heath‐Chiozzi	62
7	Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). breakdown → 2022 ·Journal of Clinical Oncology ·Xīn Gào, Howard A. Burris, Jacqueline Vuky, Robert Dreicer, Oliver Sartor, Cora N. Sternberg, Ivor Percent, Maha Hussain, Arash Rezazadeh Kalebasty, John Shen, Elisabeth I. Heath, Guillermo Abesada‐Terk, Sunil Gandhi, Meredith McKean, Haolan Lu, Elmer Berghorn, Richard Gedrich, (unknown), Nicholas J. Vogelzang, Daniel P. Petrylak	125
8	Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients 2019 ·Clinical Cancer Research ·Umamaheswar Duvvuri, Jonathan George, Seungwon Kim, Diego Alvarado, Veronique Neumeister, Ahmed Chenna, Richard Gedrich, Thomas Hawthorne, Theresa LaVallee, Jennifer R. Grandis, Julie E. Bauman	26
9	Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression 2017 ·Molecular Cancer Therapeutics ·Andrew J. Garton, Scott B. Seibel, Lori Lopresti‐Morrow, (unknown), (unknown), Sreekala Mandiyan, E. Sergio Trombetta, (unknown), Theresa LaVallee, Richard Gedrich	27
10	KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells 2016 ·Clinical Cancer Research ·Cheryl A. London, Heather L. Gardner, (unknown), Gerald Post, Krista La Perle, (unknown), Lori Lopresti‐Morrow, Andrew J. Garton, Gerald McMahon, Theresa LaVallee, Richard Gedrich	29
11	Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors 2016 ·Clinical Cancer Research ·Valentine M. Macaulay, Mark R. Middleton, Sabine Eckhardt, Charles M. Rudin, Rosalyn A. Juergens, Richard Gedrich, Sven Gogov, Sean P. McCarthy, Srinivasu Poondru, Andrew Stephens, Shirish M. Gadgeel	49
12	Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders 2015 ·Critical Reviews™ in Oncogenesis ·Theresa LaVallee, Diego Alvarado, Andrew J. Garton, E. Sergio Trombetta, Richard Gedrich, Gerald McMahon	4
13	A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours 2012 ·European Journal of Cancer ·Iain R. Macpherson, Srinivasu Poondru, George R. Simon, Richard Gedrich, (unknown), C. A. Hopkins, Kent D. Stewart, Andrew Stephens, T.R. Jeffry Evans	10
14	High-Throughput Mass Spectrometry Screening for Inhibitors of Phosphatidylserine Decarboxylase 2007 ·SLAS DISCOVERY ·(unknown), (unknown), Can C. Özbal, William A. LaMarr, (unknown), (unknown), Richard Gedrich, David G. Osterman, James A. Landro, Kevin J. Lumb	33
15	Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants 2007 ·Clinical Cancer Research ·Teresa Guida, Suresh Anaganti, (unknown), Richard Gedrich, Elizabeth Sullivan, Scott M. Wilhelm, Massimo Santoro, Francesca Carlomagno	61
16	Antitumor activity of sorafenib in FLT3-driven leukemic cells 2007 ·Leukemia ·Daniel Auclair, David F. Miller, (unknown), W C Pickett, (unknown), (unknown), (unknown), Dean Wilkie, Amy Burd, Hong Shi, (unknown), Richard Gedrich, Laura Abriola, Hema Vasavada, Mark Lynch, Jacques Dumas, Pamela A. Trail, S M Wilhelm	134
17	Translocation of TRAF Proteins Regulates Apoptotic Threshold of Cells 2000 ·Biochemical and Biophysical Research Communications ·Robert H. Arch, Richard Gedrich, Craig B. Thompson	47
18	Tumor necrosis factor receptor-associated factors (TRAFs)—a family of adapter proteins that regulates life and death breakdown → 1998 ·Genes & Development ·Robert H. Arch, Richard Gedrich, Craig B. Thompson	512
19	CD30 Contains Two Binding Sites with Different Specificities for Members of the Tumor Necrosis Factor Receptor-associated Factor Family of Signal Transducing Proteins 1996 ·Journal of Biological Chemistry ·Richard Gedrich, (unknown), Colin S. Duckett, (unknown), Craig B. Thompson	150
20	Induction of AP-1 DNA-binding activity and c-fos mRNA by the adenovirus 243R E1A protein and cyclic AMP requires domains necessary for transformation 1992 ·Journal of Virology ·Richard Gedrich, S. T. Bayley, D A Engel	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact